newsfilter
← Latest News
GlobeNewswire·

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

PROK
  • ProKidney Corp. appointed Greg Madison as Chief Commercial Officer on March 25, 2026, to drive commercial strategy for potential rilparencel commercialization.
  • Mr. Madison brings over two decades of executive leadership experience in commercial strategy, general management, launch planning, business development, and company building within biopharmaceutical firms.
  • Most recently, Mr. Madison served as CEO of Shield Therapeutics plc, where he redesigned commercial strategy, led a transformative business development transaction, and raised capital to position the company for profitability.
  • Previous roles include CEO of Melt Pharmaceuticals, President and CEO of Keryx Biopharmaceuticals, Executive Vice President and Chief Commercial Officer of AMAG Pharmaceuticals, and Vice President/General Manager of the Global Renal Business at Genzyme.
  • At Genzyme, Mr. Madison helped drive Renagel/Renvela to blockbuster status with over $1 billion in annual revenue.
  • Mr. Madison stated he is excited to join ProKidney to help shape the commercial strategy and organization for the potential launch of rilparencel as a first cell therapy for CKD patients.
  • ProKidney is evaluating rilparencel, a first-in-class autologous cell therapy, in the Phase 3 REGEN-006 (PROACT 1) study for patients with Stage 3b/4 CKD and type 2 diabetes.
  • The company notes that an estimated 37 million adults in the U.S. have CKD, with diabetes being the leading cause, creating a substantial unmet need for therapies that can stabilize kidney function.
  • The press release includes forward-looking statements regarding clinical objectives, regulatory approval, and potential commercialization, while cautioning that actual results may differ due to various risks.
  • Contact information for investor relations and media inquiries was provided for Ethan Holdaway, Daniel Ferry, and Audra Friis.